海正药业:因前期财报更正不准确收浙江证监局警示函

Core Viewpoint - The company received a warning letter from the Zhejiang Securities Regulatory Bureau regarding previous accounting errors that affected financial data from 2021 to 2024, indicating that prior financial reports were not accurate or truthful [1] Group 1: Financial Corrections - The company disclosed corrections to financial data, including revenue figures, in a public announcement made in 2025 [1] - The corrections reflect inaccuracies in previously reported financial information, which may impact stakeholder trust [1] Group 2: Management Accountability - Six individuals, including the former chairman Jiang Guoping and Shen Xinghu, were warned for failing to fulfill their responsibilities [1] - The company and the involved personnel have committed to learning from this incident and enhancing operational compliance to prevent future occurrences [1] Group 3: Operational Impact - The warning letter does not affect the company's normal operations, indicating that business activities will continue as usual despite the financial discrepancies [1]